Codexis, Inc. (CDXS)
NASDAQ: CDXS · IEX Real-Time Price · USD
3.340
+0.230 (7.40%)
At close: May 2, 2024, 4:00 PM
3.550
+0.210 (6.29%)
Pre-market: May 3, 2024, 8:45 AM EDT
Codexis Revenue
Codexis had revenue of $74.23M in the twelve months ending March 31, 2024, down -36.13% year-over-year. Revenue in the quarter ending March 31, 2024 was $17.07M with 31.51% year-over-year growth. In the year 2023, Codexis had annual revenue of $70.14M, a decrease of -49.39%.
Revenue (ttm)
$74.23M
Revenue Growth
-36.13%
P/S Ratio
3.17
Revenue / Employee
$426,632
Employees
174
Market Cap
235.66M USD
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 70.14M | -68.45M | -49.39% |
Dec 31, 2022 | 138.59M | 33.84M | 32.30% |
Dec 31, 2021 | 104.75M | 35.70M | 51.69% |
Dec 31, 2020 | 69.06M | 598.00K | 0.87% |
Dec 31, 2019 | 68.46M | 7.86M | 12.98% |
Dec 31, 2018 | 60.59M | 10.57M | 21.13% |
Dec 31, 2017 | 50.02M | 1.19M | 2.43% |
Dec 31, 2016 | 48.84M | 7.03M | 16.82% |
Dec 31, 2015 | 41.80M | 6.50M | 18.40% |
Dec 31, 2014 | 35.31M | 3.39M | 10.60% |
Dec 31, 2013 | 31.92M | -56.38M | -63.85% |
Dec 31, 2012 | 88.30M | -35.57M | -28.71% |
Dec 31, 2011 | 123.87M | 16.76M | 15.65% |
Dec 31, 2010 | 107.10M | 24.20M | 29.18% |
Dec 31, 2009 | 82.91M | 32.43M | 64.25% |
Dec 31, 2008 | 50.48M | 25.15M | 99.26% |
Dec 31, 2007 | 25.33M | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
AngioDynamics | 324.01M |
Puma Biotechnology | 226.63M |
G1 Therapeutics | 84.04M |
AVITA Medical | 51.57M |
Utah Medical Products | 50.22M |
Metagenomi | 44.76M |
AC Immune | 17.62M |
Veru Inc. | 15.93M |
CDXS News
- 14 days ago - Codexis to Report First Quarter 2024 Financial Results on May 2 - GlobeNewsWire
- 22 days ago - Codexis Appoints Carole Cobb, MBA, to Strategic Advisory Board - GlobeNewsWire
- 2 months ago - Codexis Reports Fourth Quarter and Fiscal Year 2023 Financial Results - GlobeNewsWire
- 2 months ago - Codexis Enters Exclusive Licensing Agreement for Newly Engineered Double-Stranded DNA Ligase with Roche - GlobeNewsWire
- 2 months ago - Codexis to Participate in TD Cowen 44th Annual Health Care Conference - GlobeNewsWire
- 2 months ago - Codexis Announces Appointment of Masad Damha, PhD, and Jim Lalonde, PhD, to Strategic Advisory Board - GlobeNewsWire
- 2 months ago - Codexis to Report Fourth Quarter and Fiscal Year 2023 Financial Results on February 28 - GlobeNewsWire
- 2 months ago - Codexis Secures $40 Million in Strategic Financing Deal with Innovatus Capital Partners to Further Strengthen Cash Position Ahead of Key Milestones - GlobeNewsWire